Education
About Us
Working with TipRanks
Follow Us
Johnson & Johnson (JNJ)
NYSE:JNJ
JNJ Stock Chart & Stats
Day’s Range― - ―
52-Week Range$140.68 - $169.99
Previous CloseN/A
Volume3.80M
Average Volume (3M)10.76M
Market Cap
$371.98B
Enterprise Value$365.36B
Total Cash (Recent Filing)$38.47B
Total Debt (Recent Filing)$52.25B
Price to Earnings (P/E)26.7
Beta0.30
Next Earnings
Jul 22, 2025EPS Estimate
2.68Next Dividend Ex-Date
May 27, 2025Dividend Yield3.21%
Share Statistics
EPS (TTM)2.77
Shares Outstanding2,409,847,700
10 Day Avg. Volume14,862,799
30 Day Avg. Volume10,764,838
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)4.44
Price to Cash Flow (P/CF)14.10
P/FCF Ratio14.10
Enterprise Value/Market Cap0.98
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit5.96
Enterprise Value/Ebitda10.53
Forecast
1Y Price Target
$170.36Price Target Upside9.27% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering15
---
Bulls Say, Bears Say
Bulls Say
Financial PerformanceJNJ declared a 4.8% increase in its quarterly dividend, indicating confidence in its financial strength.
Market StrategyJNJ's EP strategy is evolving to regain market share by expanding PFA offerings with new catheter form factors, evolving CARTO mapping interoperability, and building global clinical evidence.
Pharmaceutical GrowthManagement provided bullish commentary on long-term growth prospects for several key products, including Rybrevant, Spravato, Tremfya, the TARIS platform, and Icotrokinra.
Bears Say
Litigation ChallengesJNJ’s effort to resolve talc litigation through Red River Talc bankruptcy failed, and the company will return to the tort system to challenge plaintiffs.
MedTech WeaknessPharma strength offsetting Medical Device weakness and gross margin pressure balanced by lower operating costs.
Tariff ImpactJNJ expects a $400M impact in 2025 from MedTech tariffs, with the majority driven by China’s retaliatory measures.
---
Ownership Overview
0.04% Insiders
18.50% Mutual Funds
0.75% Other Institutional Investors
58.87% Public Companies and
Individual Investors
JNJ FAQ
What was Johnson & Johnson’s price range in the past 12 months?
Johnson & Johnson lowest stock price was $140.68 and its highest was $169.99 in the past 12 months.
What is Johnson & Johnson’s market cap?
Johnson & Johnson’s market cap is $371.98B.
When is Johnson & Johnson’s upcoming earnings report date?
Johnson & Johnson’s upcoming earnings report date is Jul 22, 2025 which is in 82 days.
How were Johnson & Johnson’s earnings last quarter?
Johnson & Johnson released its earnings results on Apr 15, 2025. The company reported $2.77 earnings per share for the quarter, beating the consensus estimate of $2.581 by $0.189.
Is Johnson & Johnson overvalued?
According to Wall Street analysts Johnson & Johnson’s price is currently Undervalued.
Does Johnson & Johnson pay dividends?
Johnson & Johnson pays a Quarterly dividend of $1.299 which represents an annual dividend yield of 3.21%. See more information on Johnson & Johnson dividends here
What is Johnson & Johnson’s EPS estimate?
Johnson & Johnson’s EPS estimate is 2.68.
How many shares outstanding does Johnson & Johnson have?
Johnson & Johnson has 2,409,847,700 shares outstanding.
What happened to Johnson & Johnson’s price movement after its last earnings report?
Johnson & Johnson reported an EPS of $2.77 in its last earnings report, beating expectations of $2.581. Following the earnings report the stock price went down -0.479%.
Which hedge fund is a major shareholder of Johnson & Johnson?
Currently, no hedge funds are holding shares in JNJ
---
Johnson & Johnson Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$170.36 (9.27% Upside)
$170.36 (9.27% Upside)
Blogger Sentiment
Bullish
JNJ Sentiment 92%
Sector Average 70%
Sector Average 70%
Hedge Fund Trend
Increased
By 603.6K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $3.2M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Positive
Last 7 Days ▼ 0.7%
Last 30 Days ▲ 2.2%
Last 30 Days ▲ 2.2%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
8.66%
12-Months-Change
Fundamentals
Return on Equity
29.45%
Trailing 12-Months
Asset Growth
12.62%
Trailing 12-Months
Company Description
Johnson & Johnson
Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the healthcare field worldwide. The company's Consumer Health segment offers baby care products under the JOHNSON'S and AVEENO Baby brands; oral care products under the LISTERINE brand; skin health/beauty products under the AVEENO, CLEAN & CLEAR, DR. CI:LABO, NEUTROGENA, and OGX brands; TYLENOL acetaminophen products; SUDAFED cold, flu, and allergy products; BENADRYL and ZYRTEC allergy products; MOTRIN IB ibuprofen products; NICORETTE smoking cessation products; and PEPCID acid reflux products. It also offers STAYFREE and CAREFREE sanitary pads; o.b. tampons; adhesive bandages under the BAND-AID brand; and first aid products under the NEOSPORIN brand. It serves general public, retail outlets, and distributors. The company's Pharmaceutical segment offers products for rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; HIV/AIDS and COVID-19 infectious diseases; mood disorders, neurodegenerative disorders, and schizophrenia; prostate cancer, hematologic malignancies, lung cancer, and bladder cancer; thrombosis, diabetes and macular degeneration; and pulmonary arterial hypertension. This segment serves retailers, wholesalers, distributors, hospitals, and healthcare professionals directly for prescription use. Its MedTech segment provides electrophysiology products to treat cardiovascular diseases; neurovascular care products to treat hemorrhagic and ischemic stroke; orthopaedics products in support of hips, knees, trauma, spine, sports, and other; advanced and general surgery solutions that focus on breast aesthetics, ear, nose, and throat procedures; and disposable contact lenses and ophthalmic products related to cataract and laser refractive surgery under the ACUVUE brand. This segment serves wholesalers, hospitals, and retailers. The company was founded in 1886 and is based in New Brunswick, New Jersey.
---
JNJ Company Deck
---
JNJ Earnings Call
Q1 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call reflects a strong start to 2025 for Johnson & Johnson, driven by robust sales growth in innovative medicine and MedTech, significant oncology advancements, and strategic investments. However, challenges such as the decline in STELARA sales, tariff impacts, and orthopedics disruptions pose headwinds.Read More>---
JNJ Sales Breakdown
64.13% Innovative Medicine
35.87% MedTech
---
JNJ Stock 12 Month Forecast
Average Price Target
$170.36
▲(9.27% Upside)
Technical Analysis
---